5 news items
MAIA Biotechnology (MAIA) to Showcase Groundbreaking Telomere-Targeting Cancer Treatments at BIO International Convention 2024
AFMD
ALBT
BPTH
4 Jun 24
functions by inducing telomeric DNA damage and boosting cancer-specific immune responses, potentially offering a new pathway for cancer treatment where
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
ADRT
ADSK
AFMD
3 Jun 24
. (NASDAQ:AFMD) gained 22.2% to $5.25 as the company issued follow-up data of AFM24 plus atezolizumab showing durable responses in heavily pretreated NSCLC EGFR
Why Bio-Path Stock Is Soaring
BPTH
18 Apr 24
Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Bio-Path said BP1002 may overcome and prevent some of the mechanisms
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
BPTH
18 Apr 24
targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. The current standard of care for patients
Bio-Path Holdings Provides 2024 Clinical and Operational Update
BPTH
2 Apr 24
patients, including venetoclax-resistant patients, is ongoing. BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60
- Prev
- 1
- Next